Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SGUGL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Ispectamab debotansine
|
|||||
| Synonyms |
Anti-BCMA antibody drug conjugate; BMS-986352; BMS-986352, CC-99712, SP8919; CC 99712; CC-99712; Ispectamab debotansine; SP8919
Click to Show/Hide
|
|||||
| Organization |
Sutro Biopharma, Inc.; Celgene Corp.; Bristol Myers Squibb Co.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Ispectamab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
Maytansinoid derivative
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Cys-12 ADC linker
|
Linker Info | ||||
| Conjugate Type |
Non-natural Amino Acids
|
|||||
| Combination Type |
debotansine
|
|||||
| Special Approval(s) |
Orphan drug(FDA)
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
